Arkle Resources (LON: ARK) says its partner Group Eleven Resources Corp has announced plans to drill three or four holes Stonepark zinc project in Ireland, where Arkle has a 23.4% interest. This should start in the third quarter. The costs are fully funded. The share price jumped 37.5% to 0.275p.
Brain tumour treatment developer CRISM Therapeutics Corporation (LON: CRTX) has been hit by a declining share price since joining AIM via the reverse takeover of Amur Minerals Corporation at the end of May. The opening share price was 24p and it had fallen by nearly three-quarters. Non-executive director Gerry Beaney bought 25,000 shares at 9.25p each. CRISM has developed ChemoSeed, which is a treatment for glioblastoma and high-grade glioma, which are brain tumours where there is no current cure. It is an implantable, bioresorbable drug delivery platform. The share price recovered 24% to 7.75p.
ECR Minerals (LON: ECR) has submitted 44 samples from Bailieston in Australia for testing and 12 have returned results greater than 0.1% antimony. Increasing demand for the mineral led to the reanalysing of past samples and the project is near to existing resources. The antimony price has reached record levels. The share price is 22.8% higher at 0.35p.
Market research services provider System1 Group (LON: SYS1) is reinstating its dividend following a strong recovery in pre-tax profit from £600,000 to £3.1m. Canaccord Genuity has upgraded its pre-tax profit forecast for this year from £4m to £4.4m. This is on the back of strong trading in the US. The share price rose 17.3% 610p and it has more than doubled this year.
Aptamer Group (LON: APTA) has signed an agreement with AstraZeneca to evaluate Optimer fibrotic liver delivery vehicles for the targeted delivery of siRNA provided by AstraZeneca. Optimer technology could enable targeted delivery and development of compounds that have advantages over cell and tissue-targeting methods. The share price is 8% ahead at 0.675p, having been as high as 0.75p..
FALLERS
Pharma mathematical modelling services provider Physiomics (LON: PYC) has raised £381,000 at 0.6p/share, which is 50% of the previous market price. A WRAP retail offer could raise up to £25,000. It closes at 4.30pm on 4 July. In June 2023, £380,000 was raised at 1p/share. The cash will finance the recruitment of a head of mathematical modelling service line and investment in marketing. It also wants to build a biostatics capability and implement a personalised dosing tool on the DoseMeRx platform. The share price slumped 43.8% to 0.675p.
Pubs and bars operator Nightcap (LON: NGHT) shares continue to decline ahead of its departure from AIM. Robus Capital Management has been mopping up shares and holds 14.3%. The share price slipped a further 12.3% to 2.85p.
Energy and water efficiency services provider Eneraqua Technologies (LON: ETP) says there has been a deferral of contracts due to the General Election. This means there is likely to be a greater second half weighting. A return to profit is anticipated for the second half and for the year as a whole. The share price fell 9% to 45.5p.
Machine learning technology company Insig AI (LON: INSG) has extended the redemption date of convertible loan notes has been extended to the end of September 2025. The annual interest rate on the £1m of convertibles held by chief executive Richard Bernstein will reduce from 8% to 6%. The interest rate on the £500,000 held by David Kyte remains at 12%. The share price is 7.14% lower at 16.25p.
